CSIR-NCL scientists have developed a novel process platform for the manufacturing purification of a biosimilar rHu Ranibizumab
, A novel cloning, expression refolding platform
Integrated continuous multimodal chromatography for purification
, A two-fold increase in productivity over the existing processes
, Biosimilarity has been demonstrated with Lucentis
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
National Chemical Laboratory (NCL)
Accessibility Controls